key: cord-0863724-pgpm9uns authors: Tang, Yan; Kwiatkowski, David J.; Henske, Elizabeth P. title: mTORC1 Hyperactivation in LAM Leads to ACE2 Upregulation in Type II Pneumocytes: Implications for COVID-19 date: 2020-10-16 journal: Eur Respir J DOI: 10.1183/13993003.02737-2020 sha: 65eb0ddd025ea906f91788e3e513d445b1420c35 doc_id: 863724 cord_uid: pgpm9uns Increased pneumocyte expression of the SARS-CoV-2 entry receptor ACE2 in Lymphangioleiomyomatosis (LAM) is associated with upregulation of interferon pathways in natural killer cells as wells as increased IL6 expression in LAM-associated fibroblasts. Increased pneumocyte expression of the SARS-CoV-2 entry receptor ACE2 in Lymphangioleiomyomatosis (LAM) is associated with upregulation of interferon pathways in natural killer cells as wells as increased IL6 expression in LAM-associated fibroblasts. Respiratory failure is among the gravest outcomes of COVID-19, and most of the severe cases are associated with significant lung comorbidities 1 . Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease of women caused by mutations in tuberous sclerosis genes, resulting in aberrant hyperactivation of the mTOR complex 1 (mTORC1) signaling network in LAM cells, which are of mesenchymal origin 2 . The risk of COVID-19 in LAM is unknown. We profiled the explant lungs of five women with LAM (46,659 cells) by single cell RNA sequencing (scRNA-seq) using 10x genomics Chromium platform. Low quality cells, defined as cells in which fewer than 200 different genes were detected or with mitochondrial gene percentage higher than 10%, were filtered out. Raw data was normalized, and log transformed as previously described 3 . Batch effects of datasets from different platforms were removed, and datasets were integrated using Seurat 4 . Major cells types identified in LAM using the algorithm SingleR 5 (Fig. 1a) included epithelial cells (type I and type II pneumocytes, ciliated cells), immune cells (T cells, B cells, macrophages, dendritic cells, natural killer cells), and endothelial cells (lymphatic endothelial cells and blood endothelial cells). The cell type annotation was further confirmed by plotting marker genes manually. Re-clustering of pneumocytes showed that ACE2 was primarily expressed in type II pneumocytes, while TMPRSS2 was expressed in all epithelial cell types (Fig. 1a) , consistent with prior data [6] [7] [8] . The LAM lungs were compared with existing scRNA-seq datasets (GSE122960) of healthy lungs (n=8) 9 , derived from donors who had died from stroke, hemorrhage, brain injury, or gunshot. One healthy control with an Asian genetic background was excluded because of reports that Asian individuals have higher expression of ACE2 than other populations 10 . The percentage of type II pneumocytes expressing ACE2 in LAM lungs (2.6%) was significantly higher than in healthy lungs (0.9%, p=0.03, Mann-Whitney U test, Fig. 1a ). Compared with healthy lungs, ACE2 expression was also higher in LAM-associated type I (1.5% vs. 0.7%, p=0.14) and ciliated cells (1.1% vs. 0.5%, p=0.39). TMPRRS2 expression was also significantly higher in LAM-associated type II pneumocytes (56% vs. 45%, p=0.048) (Fig. 1a) and ciliated cells (33% vs. 22%, p=0.14) compared to healthy lung. Significant upregulation of ACE2 was not observed in single cell datasets from other lung conditions compared to healthy lungs, including pulmonary fibrosis (GSE122960) (n= 4) 9 and lungs with cancer (n = 2) 8 and infectious diseases (n=6) 8 , with the exception of one lung from an HIV+ and Mycobacterium tuberculosis (TB)+ patient 8 (Fig. 1a) . These observations indicate that increased pneumocyte expression of ACE2 and TMPRSS2 is specific to LAM and not seen in other lung conditions, and suggest that the mTORC1-hyperactive LAM cells may induce this effect. shown due to limited space). These analyses demonstrate that ACE2 expression in LAM correlates with increased expression of genes whose protein products interact with, and are hypothesized to enable virus replication. To identify pathways co-regulated with the upregulation of ACE2 in LAM, we performed pathway analysis, comparing expression of ACE2+ vs. ACE2-epithelial cells in the LAM dataset. Both hypoxia and IL-6-induced acute-phase response pathways were upregulated in the LAM ACE2+ pneumocytes. The master transcription factor of the IL-6 pathway, STAT3, was upregulated in LAM ACE2+ pneumocytes, along with four genes directly or indirectly regulated by STAT3: FGG, CXCL1, HP, and HMOX1 (Fig. 1b) , suggesting IL-6 might be driving these effects. Consistent with this, we found increased IL-6 in LAM-associated fibroblasts compared to mesenchymal cells derived healthy lungs (Fig. 1b) , supporting the concept that IL-6 drives ACE2 expression in LAM. ACE2 is an interferon-stimulated gene in human airway epithelial cells 12 . We used lists of genes involved in IFN-alpha/beta signaling via JAK/STAT (type I) and interferon gamma (type II) signaling pathways (MetaCore from Clarivate Analytics) to calculate cell type-specific interferon pathway activity scores in healthy lungs compared with LAM lungs 4 . In the LAM lungs, both type I and type II interferon pathways were upregulated in natural killer (NK), but not in T cell, B cells, or macrophages (Fig. 1b) . Many key regulators in the IFN pathways were significantly upregulated in LAM NK cells, including INFG and INFGR1 (Fig. 1b) . In addition, interferon gamma expression was upregulated in LAM-associated NK cells compared to healthy lungs (Fig. 1b) . These analyses suggest that interferon secretion by LAM NK cells into the tumor microenvironment may cooperate with IL-6 to upregulate ACE2 expression in LAM epithelial cells (Fig. 1b) . mTORC1, which is hyperactive in LAM, promotes protein synthesis and cellular growth, and is believed to be used by SARS-CoV-2 to favor replication 13 Therefore, we investigated the effect of rapamycin (an allosteric mTORC1 inhibitor) on gene expression in these pathways in primary cells, derived from a dissociated renal angiomyolipoma tumor carrying a TSC2 mutation obtained at the time of surgery. Angiomyolipomas are benign tumors that share common genetic mutations with LAM and occur in half of women with LAM. Primary cultures were treated with 20nM rapamycin or DMSO for 24 hours and subjected to single cell profiling. To overcome the challenge of inflated zeroes in single cell data, we used MAGIC 15 to impute gene expression in each cell. Using the same pathway gene lists described above (MetaCore from Clarivate Analytics), we observed that rapamycin treatment had major effects in downregulating both type I and type II interferon pathways (Mann-Whitney U-test p<2.2E-16 for all comparisons) (Fig. 1c) , including many interferon stimulated genes (e.g. IFIT, Interferon Induced Protein With Tetratricopeptide Repeats family) (Mann-Whitney U test p<0.001 for all genes) (Fig. 1d) . IL-6-induced acute-phase response genes that were enriched in ACE2+ cells were also downregulated by rapamycin treatment (Mann-Whitney U-test p<0.001) (Fig. 1d) . The expression of the 332 SARS-CoV-2-interacting host proteins also showed downregulation by rapamycin treatment in general (data not shown due to limited space). These analyses suggest that mTORC1 inhibition may have benefit in SARS-CoV-2 by decreasing the IFN and IL6 pathways that promote the expression of ACE2. In conclusion, we observed an increased percentage of type II pneumocytes expressing ACE2 in LAM lungs, associated with upregulation of the Type I and Type II interferon pathways in LAM-associated NK cells, and increased IL6 expression in LAM-associated fibroblasts, suggesting that both mechanisms drive increased ACE2 expression. Similar mTORC1dependent mechanisms may contribute to ACE2 expression in other settings. An advantage of using LAM as a model system is the consistent activation of mTORC1 within LAM cells. While other tumors often have elevated mTORC1 activity, it is rarely present as a single, defining genetic feature, making it much more difficult to pinpoint these types of non-cell autonomous mechanisms. How mTORC1 signaling within tumor cells impacts ACE2 expression in neighboring epithelial cells will require additional single-cell datasets using genetically defined specimens, and/or mouse models in which mTORC1 is specifically perturbed. Alterations in mTORC1 signaling may also be present in non-malignant disorders such as IPF. We analyzed a published single cell dataset of four IPF samples, and did not find a significant increase in ACE2 expression in type II pneumocytes compared to healthy donors. Notably, using cultured primary cells from a LAM-related tumor, angiomyolipoma, we discovered that rapamycin treatment downregulated the interferon pathways and also downregulated a set of previously identified putative SARS-CoV2-interacting proteins. From a clinical perspective, the upregulation of ACE2/TMPRSS expression in LAM lung epithelial cells suggests that women with LAM may be at increased risk of severe COVID-19 infection. Although all of the LAM specimens studied here are from lung transplantation tissue representing advanced disease, since our analyses link mTORC1 activity to the expression of ACE2 and TMPRSS2, we speculate that this would also be true in mild disease. Future studies will be needed to confirm this. The downregulation of IL-6 and interferon signaling in response to rapamycin suggests that rapamycin treatment may have benefit both in limiting initial infection upon virus exposure and progression of COVID-19 to pneumonia both in general and in women with LAM. This is particularly important for patients already taking rapamycin for LAM or other diseases. Further analyses including clinical trials will be necessary to assess the potential benefit of rapamycin for both aspects of COVID-19. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan Lymphangioleiomyomatosis -a wolf in sheep's clothing Integrating single-cell transcriptomic data across different conditions, technologies, and species Comprehensive Integration of Single-Cell Data Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations A SARS-CoV-2 protein interaction map reveals targets for drug repurposing SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues Influenza virus differentially activates mTORC1 and mTORC2 signaling to maximize late stage replication Dysregulation in mTOR/HIF-1 signaling identified by proteotranscriptomics of SARS-CoV-2 infected cells. bioRxiv Recovering Gene Interactions from Single-Cell Data Using Data Diffusion Y. T. is the recipient of a Career Development Award from The LAM Foundation and a grant from the DOD Tuberous Sclerosis Complex Research Program (W81XWH1910152-TS180029). We also thank the Rothberg Family for their support of this work. There is no conflict of interest to report and the authors declare no competing financial interests.